Mintz Life Sciences Deal Activity (April – June 2020)
M&A
- Represented Censa Pharmaceuticals, Inc. in its sale to PTC Therapeutics, Inc. (May 2020)
- Represented Neurotrope, Inc. in its merger agreement with Metuchen Pharmaceuticals, LLC to form Petros Pharmaceuticals, a men’s health company (May 2020)
- Represented HealthpointCapital, a private equity firm focused on the musculoskeletal industry, in its acquisition of a majority stake in IlluminOss Medical Inc. (May 2020)
VC
- Represented Matrix Capital Management in its $43.7M Series C investment in a clinical data analytics company (June 2020)
- Represented Matrix Capital Management in its $25M Series D Investment in a cancer therapeutic company (June 2020)
- Represented Inhibrx, Inc. in its $15M Convertible Note financing (April 2020)
- Represented MitoLab Inc. in its $3M Series Seed financing (April 2020)
Capital Markets
Represented the issuer:
- Evofem Inc. in its $100M public offering underwritten by Morgan Stanley, Piper Sandler, Oppenheimer & Co. Inc., H.C. Wainwright & Co., LLC (June 2020)
- Viela Bio, Inc. in its $169M public offering underwritten by Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Guggenheim Securities (June 2020)
- Bellerophon Therapeutics, Inc. in its $25M public offering underwritten by Jefferies and concurrent $15M registered direct offering (May 2020)
- Caladrius Biosciences, Inc. in its $4.3M registered direct offering placed by H.C. Wainwright & Co. and Arcadia Securities (May 2020)
- Evofem Inc. in its $25M PIPE financing (April 2020)
Represented the underwriters:
- Acceleron Pharma Inc. in its $450M public offering underwritten by J.P. Morgan, SVB Leerink, Cowen, Barclays, Credit Suisse, Piper Sandler and H.C. Wainwright & Co. (June 2020)
- Soleno Therapeutics, Inc. in its $50M public offering underwritten by Guggenheim Securities, Oppenheimer & Co. and Laidlaw & Company (UK) Ltd. (June 2020)
- Soliton, Inc. in its $35M public offering underwritten by Cantor, Oppenheimer & Co. and Maxim Group LLC (June 2020)
- Celsion Corporation in its $10M registered direct offering underwritten by Oppenheimer & Co. Inc. (June 2020)
- Leap Therapeutics, Inc. in its $45M public offering underwritten by Piper Sandler, Raymond James, Baird, H.C. Wainwright & Co. and Ladenburg Thalmann (June 2020)
- Cerecor Inc. in its $33M public offering underwritten by Oppenheimer & Co. Inc. (June 2020)
- Mersana Therapeutics, Inc. in its $152M public offering underwritten by Cowen, SVB Leerink, Wedbush PacGrow, Baird and H.C. Wainwright & Co. (May 2020)
- Geron Corporation in its $150M public offering underwritten by Stifel, MTS Health Partners, Needham & Company, BTIG and H.C. Wainwright & Co. (May 2020)
- NeuBase Therapeutics, Inc. in its $31.5M public offering underwritten by Oppenheimer & Co., BTIG, Chardan and National Securities Corporation (April 2020)
- Fennec Pharmaceuticals Inc. in its $30M public offering underwritten by Cantor and Wedbush PacGrow (April 2020)
- Bionano Genomics, Inc. in its $18M public offering underwritten by Oppenheimer & Co. Inc., Roth Capital Partners and Maxim Group, LLC (April 2020)
Represented the sales agent / placement agent:
- Compass Therapeutics in its $60M private placement with Raymond James, B. Riley FBR, and Katalyst Securities, LLC as placement agents (June 2020)
- Ocuphire Pharma, Inc. in its $21.5M private placement with Cantor and Canaccord Genuity as placement agents (June 2020)
- Axovant Gene Therapies Ltd. In its $25M at-the-market offering with SVB Leerink as sales agent (April 2020)
View Deal Activity from July – September 2020
View Deal Activity from October – December 2020
View Deal Activity from January – March 2021